The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS. The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period and further investigating the co-variates or co-medications that affect the pharmacokinetics of pitolisant in the target population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
389
Specialised Hospital for Active Treatment of pneumo-phthisiatric diseases - Burgas" EOOD, Pneumology ward
Burgas, Bulgaria
Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EOOD
Kozloduy, Bulgaria
Multiprofile Hospital for Active Treatment "Sv. Paraskeva" OOD
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Kaspela" EOOD Clinic of thoracic surgery
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD
Sofia, Bulgaria
Hospital of Skopje
Skopje, North Macedonia
Epworth sleepiness scale (ESS)
Change from Baseline of ESS
Time frame: at weeks 12 and 52
Percentage of ESS responders
Percentage of ESS responders
Time frame: at weeks 12 and 52
Reduction of sleepiness and sleep episodes on the sleep diary
Reduction of sleepiness and sleep episodes
Time frame: at weeks 12 and 52
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
Time frame: at weeks 12 and 52
European Quality of Life Questionnaire (EQ-5D)
EQ-5D improvement (mobility, self-care, usual activities, pain/discomfort and anxiety/depression)
Time frame: at weeks 12 and 52
Leeds Sleep Evaluation Questionnaire (LSEQ)
LSEQ improvement (changes in sleep and next morning behaviour during disease/pharmacological investigations)
Time frame: at weeks 12 and 52
The Pichot Fatigue Scale
Pichot Fatigue scale improvement (assessment of the level of discomfort caused by a state of fatigue)
Time frame: at weeks 12 and 52
Trail Making Test parts (A and B)
TMT test improvement
Time frame: at weeks 12 and 52
Improvement in Clinical Global Impression (CGI)
CGI improvement (patient progress and treatment response over time)
Time frame: at weeks 12 and 52
Aggregate Z-score of secondary endpoints.
Aggregate Z-score of secondary endpoints improvement
Time frame: at weeks 12 and 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.